New quick MRI could slash prostate cancer scan costs by 30%
NCT ID NCT05046782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test an abbreviated MRI method (using restriction spectrum imaging plus T2-weighted images) for detecting prostate cancer, comparing it to the standard multiparametric MRI. The goal was to see if the faster, cheaper scan could find cancer just as well, while avoiding contrast dye and reducing scan time and cost. However, the study was withdrawn before any participants were enrolled, so no results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- restriction spectrum imaging (RSI) MRI device
- What this could lead to
- If successful, this could provide a faster, cheaper, and safer MRI option for prostate cancer detection, reducing scan time and cost by up to 40%.
- What could go wrong
- The study was withdrawn before enrolling any participants, so no results are available. The approach may not prove as accurate as standard MRI in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?